XML 49 R34.htm IDEA: XBRL DOCUMENT v3.24.4
BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES - Revenues disaggregated by our business operations and timing of revenue recognition (Details) - USD ($)
 12 Months Ended
Sep. 30, 2024
Sep. 30, 2023
BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES    
Total $ 3,431,420 $ 13,367,443
Research and development services (over-time)    
BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES    
Total 311,238 421,585
Clinical laboratory testing services (point-in-time)    
BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES    
Total 32,610 7,612,975
Clinical laboratory services (over-time)    
BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES    
Total 1,285,320 3,540,456
Supply chain    
BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES    
Total 1,208,696 827,603
Large Scale DNA Production    
BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES    
Total 584,115 653,015
Asset marking    
BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES    
Total $ 9,441 $ 311,809
LineaRx, Inc.    
BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES    
Percentage of ownership held in Subsidiary 98.00%